Biohaven (BHVN) has entered a multi-program research collaboration with Bexorg to advance next-generation therapies for central nervous system disorders, Bexorg said Tuesday.
Financial details weren't disclosed.
As part of the collaboration, Bexorg will apply its proprietary whole-brain discovery platform to support two of Biohaven's preclinical development programs, with an aim to generate detailed insights into target engagement, pharmacokinetics, pharmacodynamics, and mechanisms of action for Biohaven's investigational therapies.
Price: 16.92, Change: -0.14, Percent Change: -0.81
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.